The Effects of Gonadotropin Replacement Therapy in Patients With Hypogonadism

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02042638

Enrollment

Registered

2014-01-23

Start date

2011-01-31

Completion date

2013-08-31

Last updated

2014-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Hypogonadotropic Hypogonadism

Brief summary

Effects of hCG replacement therapy on metabolic syndrome parameters in hypogonadotrophic hypogonadism.

Interventions

DRUGhCG 1500 IU three times a week

DRUGPregnyl (hCG) ampule 1500 IU/three times a week

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

16 Years to 45 Years

Healthy volunteers

Inclusion criteria

Serum testosterone concentration \< 300ng/dL Absence of a pituitary or hypothalamic mass lesions, Presence of gonadotropin response to GnRH, -

Exclusion criteria

Previous androgen treatment, diabetes mellitus, arterial hypertension other hormone deficiencies \-

Design outcomes

Primary

Measure	Time frame	Description
HDL after hCG treatment	2011-2013	2011-2013
LDL levels after hCG treatment	2011-2013	—
total cholesterole levels after hCG treatment	2011-2013	—

Secondary

Measure	Time frame
Body fat ratio after hCG treatment	2011-2013
hsCRP levels after hCG treatment	2011-2013

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026